About Cellphire


Overview

Cellphire, Inc. is a biotechnology company established in 2005. The company focus is on developing stabilized cellular materials for advanced technologies in the therapeutic and diagnostic markets through its proprietary cell stabilization technology. Cellphire is commercializing freeze-dried platelet-derived products with an initial focus on applications within the global blood and blood supply markets.

Cellphire is developing technology and products that have potential applications in diverse health care fields from trauma to wound care, imaging, targeted drug delivery, and regenerative medicine.

The fragility of the national supply of platelets is a topic of discussion of several task forces and agencies planning the nation's response to a pandemic such as avian influenza. This and other natural or man-made disasters would interrupt the constant supply of platelets that is needed to maintain an adequate supply or treat bleeding casualties. 

Message from the CEO:

The underlying technology that Cellphire has developed promises to provide a quantum leap forward in how cells are handled and used within health care today. Our initial application, platelets, is a perfect example. Untreated platelets last five days outside of a donor’s body: with our patented treatment, we are able to freeze dry platelet-derived products for storage measured in years, at room temperature. Reconstitution is as simple as adding sterile water.

With the support of the Biomedical Advanced Research Defense Authority (BARDA), a division of U.S. Department of Health & Human Services, and their $57 million grant to us, we have the ability and resources to take this product far down the road through a Phase 2 clinical trial and eventually FDA approval. BARDA is interested because this product has the potential to be the first and only product to remediate a key problem caused by exposure to radiation. Our reconstituted freeze-dried platelets (Thrombosomes®) have been shown, in animals, to have profound benefits in wound healing. Thrombosomes® have the potential to be powerful imaging agents; to assist in sports medicine, plastic surgery, dentistry; as well as other applications. Our underlying cell stabilization technology has application to other cell types as well.

Our fundamental mission is to obtain FDA approval of Thrombosomes® as a hemostatic agent to stop active bleeding in surgical or thrombocytopenic patients while BARDA’s interest is in the use of Thrombosomes® for treatment of acute radiation sickness. We can pursue other applications as well, because the same technology is used in each of them. To do them as well, we will seek additional partners in each related field. By continuing our unique ability to stabilize cells with leading companies in key therapeutic areas, we seek to make a major difference in health care in the United States and around the world.

Sincerely,
Stephen H Willard
CEO

cellphire-img

Leadership


MANAGEMENT:

Stephen H. Willard - Chief Executive Officer and Director
Before joining Cellphire in 2013, Mr. Willard served as CEO and Chairman of the Board of Flamel Technologies, a NASDAQ-traded biotech company with a market capitalization in excess of $1 billion under his leadership. He has served as Chief Financial Officer and General Counsel of publicly traded companies, as well as an investment banker and attorney in private practice. Mr. Willard served as a director of E*Trade Bank and E*Trade Financial Corporation for a total of 14 years, including a period as Vice Chairman. He received a B.A. from Williams College and a Juris Doctorate from Yale Law School. Mr. Willard is currently a member of the National Science Board.

G. Michael Fitzpatrick, Ph.D. - President & Director of R&D
Dr. Fitzpatrick has more than 40 years of military and civilian blood banking and biomedical experience. He joined Cellphire in 2006 and has led the development of the company’s first line of hemostatic products. Prior to joining Cellphire, Dr. Fitzpatrick served as Chief Operating Officer of America’s Blood Centers, North America’s largest network of non-profit community blood centers. Previously, he served 29 years in the U.S. Army, retiring as a Colonel in 2003. Throughout his military career, Dr. Fitzpatrick was involved in clinical transfusion medicine, blood collection and delivery, and clinical research. He also provided oversight and planning of blood support operations to ensure delivery of blood and blood products to deployed troops. From 1999-2003, Dr. Fitzpatrick served as Director of the Armed Services Program, the sole provider of blood products to the U.S. Armed Forces. His other assignments included serving as the Korea Area Blood Program Officer; United States European Command Blood Program Officer; and Chief of Transfusion Services and Blood Donor Center for Madigan Army Medical Center, Tripler Army Medical Center, and Walter Reed Army Medical Center. He also served as the Director of the Tri-Service Blood Bank Fellowship at Walter Reed. Dr. Fitzpatrick received a Bachelor of Science from Colorado State University and a Master of Science and Ph.D. in Immunohematology from Bowling Green State University.

Rafael Jorda - Executive Vice President
Mr. Jorda has extensive experience in the life sciences industry as a scientist and business leader. For more than 25 years, he has managed the research and development, production, intellectual property, and business development operations within both pharmaceutical and biotechnology companies. Mr. Jorda is a co-founder of Flamel Technologies. He led the company’s research and manufacturing operations, helping take Flamel public in 1996. Mr. Jorda also worked in the polymer research group of Rhône-Poulenc. In research, he has focused chiefly on developing technologies based on nano- and microparticles for targeted oral and injectable drug delivery systems. Mr. Jorda holds a Master of Science in Chemical Engineering from Virginia Tech for which he wrote his thesis on biodegradable polymers. He also received a Master of Science in Chemistry from ENSCM, University of Montpellier (France).

Anne Hale, DVM - Chief Technical Officer, BodeVet, Inc. (Cellphire veterinary subsidiary)
Dr. Hale is a renowned expert in veterinary transfusion medicine. Residency trained in Small Animal Internal Medicine, she was an NIH Comparative Fellow in Transfusion Medicine at Michigan State University. Dr. Hale founded and guided Midwest Animal Blood Services, an internationally known blood bank. She worked as the CEO and Director for Animal Blood Resources International while the company launched a new line of lyophilized blood products. Dr. Hale is currently Chief Science Officer of The Platelet Farm, managing the research and commercialization of veterinary blood products (including freeze-dried equine platelet lysate). In addition, she has been in practice limited to Internal Medicine and Critical Care for 28 years, most recently at the Veterinary Emergency and Specialist Centers in New Mexico. Dr. Hale is a founding member of the American Association of Veterinary Blood Banks and is an active member of many other like organizations, including the American Veterinary Medical Association, the North American Veterinary Regenerative Medicine Association, and the Association of Veterinary Hematology and Transfusion Medicine. She is also a scientific advisor for The Pet Blood Bank UK.

Thomas S. Dann - Chief Investment Officer
Mr. Dann has almost 20 years’ experience in technology investing and company building. He was previously Managing Director of two early stage venture funds, the Maryland Venture Fund and ECentury Capital Partners. He also formerly served as a director of Global Internet Ventures, LLC and as Founder and Managing Director of Castlehaven Advisors, LLC. During his venture career, Mr. Dann served as a director of numerous early stage companies, as well as a Director of the Mid-Atlantic Venture Association. He received a B.A. degree from Stanford University and a Juris Doctorate from American University Law School.

Keith A. Moskowitz, Ph.D. MPM - Vice President of Discovery
Dr. Moskowitz has 25 years of leadership experience directing research and development (R&D) and strategy in companies with revenues of more than $1 billion. He has held technical, management, and liaison positions in the areas of hemostasis and thrombosis, infectious, and genetic diseases in a variety of medical industries, including biologicals. Previously, Dr. Moskowitz served as Vice President of Technology and Development at PTS Diagnostics; Vice President of Product Development & Medical Science Liaison at TraumaCure; Vice President of Product Development at BioMarker Strategies; and Director of Corporate Product Development at SeraCare Life Sciences. He also served as Director of Hematology and R&D at Adlyfe and Accumetrics. Dr. Moskowitz received a Bachelor of Science from Rutgers University and a Ph.D. in Biochemistry from Temple University School of Medicine. He is the author of more than 50 peer reviewed publications, abstracts, and patents and is a member of the American Society of Hematology; The International Society for Hemostasis and Thrombosis; and the American Association of Clinical Pathologists. 

CLINICAL CONSULTANTS:

John B. Holcomb, M.D., F.A.C.S:
Dr. Holcomb has extensive experience in the treatment of military and civilian trauma patients and has led three major trauma clinical trials in the past decade. He is a 23-year veteran of the U.S. Army, retiring as a Colonel in 2008. Throughout his military career, he was deployed in support of multiple combat operations, first serving with the Joint Special Operations Command. From 2002 until 2008, Dr. Holcomb was the Commander of the U.S. Army Institute of Surgical Research and served as Trauma Consultant for the U.S. Army Surgeon General. After retiring from military service, Dr. Holcomb joined the University of Texas Health Science Center at Houston as Professor of Surgery. He was subsequently named the Chief, Division of Acute Care Surgery; Director of the Center for Translational Injury Research; and Vice Chair of the Department of Surgery. In 2017, Dr. Holcomb transitioned to part-time status at the University, where he is focused on entrepreneurship, innovation, and business and regulatory strategy. He most recently served as Chief Medical Officer for Prytime Medical. Dr. Holcomb received a Bachelor of Science from Centenary College and his Medical Doctorate from the University of Arkansas Medical School. He is a Fellow of the American College of Surgeons.

BOARD OF DIRECTORS:

John Ludwig Vogelstein (Chairman)
Mr. Vogelstein was a co-founder of Warburg Pincus LLC and remains a special limited partner. For more than 30 years, he served as President of Warburg Pincus. Prior to joining Warburg, Mr. Vogelstein was a partner of Lazard Freres & Co. He is chairman emeritus of the New York City Ballet and of Prep for Prep; chairman of Third Way; vice chairman of the board of overseers of The Leonard N. Stern School of Business at New York University; trustee of New York University; trustee of Temple Emanu-El; and a life trustee of The Jewish Museum. He attended Harvard College.

James B. Peake, MD, Lt. Gen. (Ret.)
Dr. Peake is Senior Vice President of CGI Federal. Previously he served as U.S. Secretary of Veterans Affairs. He is a retired U.S. Army Lieutenant General and served as the Army Surgeon General. As Army Surgeon General, Dr. Peake commanded 50,000 medical personnel and 187 army medical facilities worldwide. Prior to that, he served as Commanding General of the U.S. Army Medical Department Center and School, one of the largest medical training facilities in the world with 30,000 students annually. In addition, he was the Executive Vice President and Chief Operating Officer of Project Hope. Dr. Peake received his Bachelor of Science from the U.S. Military Academy at West Point in 1966. Following service in Vietnam with the 101st Airborne Division, where he was awarded the Silver Star, a Bronze Star with “V” device and the Purple Heart with oak leaf cluster, Dr. Peake received his medical doctorate from Cornell University.

Rodman W. Moorhead III
Mr. Moorhead retired from Warburg Pincus, a global private equity firm, after a career spanning 37 years. His last position at Warburg Pincus was as Senior Advisor and Managing Director of their Life Sciences practice. He is Chairman of the Board of The Taft School, a member of the Harvard Medical School Board of Fellows, Chairman of Stroud Water Research Center, trustee of the Brandywine Conservancy and trustee of the Jackson Hole Land Trust. Mr. Moorhead holds an AB in Economics from Harvard College and a Master of Business Administration from Harvard Business School.

David I. Hirsh, Ph.D.
Dr. Hirsh is a Professor in the Department of Biochemistry and Molecular Biophysics at the College of Physicians and Surgeons of Columbia University. He has served as Chairman of the Department and as Executive Vice President of Research at Columbia University. Dr. Hirsh also worked as the Executive Vice President and Director of Research at Synergen Inc. He is Chairman of the Board of the New York Structural Biology Center and a Member of the Boards of Rockefeller University and the Agouron Institute. Dr. Hirsh formerly served as the Chairman of Life Sciences Advisory Board at Warburg Pincus LLC and as a Director of several biotechnology companies. He received a B.A. degree from Reed College, a Ph.D. in Biochemistry from Rockefeller University, and did postdoctoral studies at the Medical Research Council in Cambridge, England. 

Have Questions?Reach us here

Please enter your information below

The Cellphire Method

Cellphire has developed a proprietary method for the long-term stabilization of blood cells in the dry state. The first application of this technology is to develop a freeze-dried hemostatic agent derived from platelets.